OIMU
ALNY icon

Osmosis Investment Management UK’s Alnylam Pharmaceuticals ALNY Stock Holding History

Osmosis Investment Management UK’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Sell
3,638
-3,375
-48% -$1.02M 0.05% 261
2026
Q1 		$2.32M Sell
7,013
-694
-9% -$236K 0.06% 228
2025
Q4 		$3.06M Buy
+7,707
New +$3.41M 0.08% 219

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osmosis Investment Management UK's ALNY Position: Q2 2026 in Review

Osmosis Investment Management UK reduced its Alnylam Pharmaceuticals (ALNY) stake by 48% in Q2 2026, selling an estimated $1.02M and leaving 3,638 shares worth $1.1M. The position accounts for 0.05% of the portfolio, ranked #261.

Osmosis Investment Management UK first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.06M in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Osmosis Investment Management UK held 3,638 shares of Alnylam Pharmaceuticals worth $1.1M as of Q2 2026.
  • Osmosis Investment Management UK sold 3,375 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.02M.
  • Alnylam Pharmaceuticals made up 0.05% of Osmosis Investment Management UK's portfolio in Q2 2026, its #261 holding.
  • Osmosis Investment Management UK first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Osmosis Investment Management UK's Alnylam Pharmaceuticals position peaked at $3.06M in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Osmosis Investment Management UK's 13F filing for Q2 2026, filed 13 Aug 2026.